| # | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
|---|
D. Boral Capital analyst Jason Kolbert maintains Pulmonx (NASDAQ:LUNG) with a Buy and maintains $16 price target.
Jaeger™ Medical, a global leader in respiratory diagnostic products, is pleased to announce a strategic partnership with Pulmon...
Wells Fargo analyst Larry Biegelsen maintains Pulmonx (NASDAQ:LUNG) with a Equal-Weight and lowers the price target from $6 ...
Lake Street analyst Frank Takkinen maintains Pulmonx (NASDAQ:LUNG) with a Buy and lowers the price target from $12 to $8.